Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current treatment options for malignant melanoma

G L Cohen1, C I Falkson

  • 1Department of Medical Oncology, Faculty of Medicine, University of Pretoria, Republic of South Africa.

Drugs
|June 9, 1998
PubMed
Summary

Malignant melanoma incidence is rising, necessitating improved treatments. Interferon-alpha (IFN-alpha) is the only adjuvant therapy proven to improve survival for high-risk melanoma patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When does a man need a check-up?

Canadian family physician Medecin de famille canadien·2011
Same author

Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2003
Same author

Dubious about Depakote.

Headache·2001
Same author

Absence of commonly recurring BRCA1 mutations in black South African women with breast cancer.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2000
Same author

21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature.

American journal of clinical oncology·2000
Same author

Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2000

Area of Science:

  • Oncology
  • Dermatology
  • Public Health

Background:

  • Malignant melanoma incidence is rapidly increasing globally.
  • Primary prevention through sun exposure education is crucial but slow-acting.
  • Medical oncologists face rising numbers of patients requiring adjuvant and metastatic melanoma treatment.

Purpose of the Study:

  • To review current and emerging treatment strategies for malignant melanoma.
  • To highlight the role of adjuvant therapy and management of metastatic disease.
  • To discuss the efficacy and limitations of various therapeutic approaches.

Main Methods:

  • Review of existing literature on malignant melanoma treatments.
  • Analysis of adjuvant therapies, including interferon-alpha (IFN-alpha).
  • Evaluation of chemotherapy, immunotherapy, and novel treatment modalities.

Main Results:

  • Interferon-alpha (IFN-alpha) is the sole adjuvant therapy demonstrated to improve disease-free and overall survival in high-risk melanoma.
  • Chemotherapy (dacarbazine/DTIC) remains a standard, with combination chemotherapy not yet proven superior.
  • Immunotherapy (IFNs, IL-2) shows results comparable to chemotherapy; combination chemo-immunotherapy offers promise but with toxicity.
  • Novel therapies like tumor vaccines and gene therapy are under investigation.

Conclusions:

  • Adjuvant interferon-alpha (IFN-alpha) offers a survival benefit for high-risk melanoma patients.
  • While progress is made in metastatic melanoma, combination therapies and novel treatments show future promise.
  • Continued research and clinical trials are essential for advancing melanoma management.

Related Experiment Videos